Novartis Posts Lower-Than-Expected Earnings in Q4

Novartis is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment. Novartis’ blockbuster drug, Diovan lost exclusivity both in the U.S. and EU and entry of generics is impacting the top-line.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.